Articles & Video
REPORT: COVID-19 Response in Cell & Gene Therapy Manufacturing 2021
This exclusive report uncovers the major changes in the cell and gene therapy sector during the COVID-19 pandemic.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
Life Sciences Survey: COVID-19 Impacts One Year On
Take part in our industry survey on the impacts of COVID-19 on the life sciences one year on to get exclusive early access to the final report.
63% of cell and gene therapy professionals changed their supply chain strategies due to COVID-19
We examine new data on the challenges in cell and gene therapy supply chain and manufacturing as a result of the COVID-19 pandemic.
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
Post-event Report: Cell & Gene Therapy Bioprocessing & Commercialization 2020
We review the key highlights from the virtual conference, including analysis of the hottest sessions by BioProcess International magazine.
Pharma’s role in maintaining cancer mortality progress during COVID-19
COVID-19 is threatening the progress made in reducing cancer mortality. Pharma has a pivotal role to play in helping patients and providers navigate the new reality of cancer treatment during the pandemic, and beyond.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Automating cell and gene therapy manufacturing: challenges and approaches
With the pressure on to scale up manufacturing of cell and gene therapies, what steps should organizations take to optimize their processes with automation? We asked three industry experts for their advice.
80% of life sciences professionals predict a COVID-19 vaccine will be approved within 18 months
How quickly to life sciences professionals predict a COVID-19 vaccine will be approved and what are the main obstacles? We explore.
COVID-19 Report: The Response to and Impacts on the Global Life Sciences Industry
COVID-19 Report: How is the life sciences industry developing a vaccine, treatment and testing for COVID-19 and what impact is it having on supply chain?
What can reduce the cost of CAR-T therapy? - INDUSTRY VOICES
With such a high demand, what are the best available ways to lower the cost of CAR-T therapy? We ask three industry experts.
REPORT: Cell and Gene Therapy Analytics, Manufacturing and Supply Chain
Explore and download our latest data report on Cell and Gene Therapy Analytics, Manufacturing and Supply Chain, in partnership with Intertek.
How Kite Pharma built a robust CAR-T supply chain
How did Kite Pharma build its robust supply chain for CAR-T therapies without a precedent? We found out from Director of Global Supply Chain David Kim and Sr. Manager of Packaging Engineering, Craig Vermeyen.
INDUSTRY VOICES: Tackling the downstream supply chain challenges of cell and gene therapies
How can specific challenges affecting the downstream supply chain for cell and gene therapies be addressed? These industry experts gave us their view.
Is cell therapy manufacturing a supply chain challenge at its core?
GE Healthcare discuss how a paradigm shift in the cell therapy supply chain could help overcome many of the biggest challenges facing the cell therapy industry.